XML 19 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Revenue
 3 Months Ended
Mar. 31, 2022
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
The following table summarizes our revenue recognized in our consolidated condensed statements of operations:
Three Months Ended March 31,
 20222021
Net product revenue$7,132.9 $6,320.0 
Collaboration and other revenue(1)
677.1 485.6 
Revenue$7,810.0 $6,805.6 
(1) Collaboration and other revenue associated with prior period transfers of intellectual property was $53.2 million and $43.0 million during the three months ended March 31, 2022 and 2021, respectively.
We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements includes our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Jardiance® and Trajenta® families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.
Adjustments to Revenue
Adjustments to increase revenue recognized as a result of changes in estimates for our most significant United States (U.S.) sales returns, rebates, and discounts liability balances for products shipped in previous periods were less than 1 percent of U.S. revenue during each of the three months ended March 31, 2022 and 2021.
Contract Liabilities
Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract.
The following table summarizes contract liability balances:
 March 31, 2022December 31, 2021
Contract liabilities$251.6 $262.6 
During the three months ended March 31, 2022 and 2021, revenue recognized from contract liabilities as of the beginning of the respective year was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.
Disaggregation of Revenue
The following table summarizes revenue by product for the three months ended March 31, 2022 and 2021:
Three Months Ended March 31,
 20222021
U.S.
Outside U.S.Total
U.S.
Outside U.S.Total
Revenue—to unaffiliated customers:
Diabetes:
Trulicity®
$1,313.9 $427.4 $1,741.3 $1,116.8 $335.7 $1,452.4 
Humalog® (1)
368.9 249.3 618.2 332.7 284.4 617.0 
Jardiance(2)
229.8 189.7 419.4 151.2 160.8 312.0 
Humulin®
190.4 82.8 273.2 219.0 102.7 321.7 
Basaglar®
119.3 72.2 191.5 175.2 71.4 246.6 
Other diabetes54.3 90.2 144.6 66.3 94.9 161.4 
Total diabetes2,276.6 1,111.6 3,388.2 2,061.2 1,049.9 3,111.1 
Oncology:
Verzenio®
301.5 167.9 469.4 172.8 96.2 269.0 
Alimta®
254.3 89.7 343.9 261.1 297.8 559.0 
Cyramza®
79.2 151.1 230.3 80.2 160.3 240.5 
Erbitux®
109.7 13.0 122.7 107.9 14.4 122.4 
Tyvyt®
— 85.5 85.5 — 109.7 109.7 
Other oncology39.0 62.0 101.2 20.5 51.3 71.6 
Total oncology783.7 569.2 1,353.0 642.5 729.7 1,372.2 
Immunology:
Taltz®
307.2 180.8 488.1 249.6 153.6 403.2 
Olumiant® (3)
71.3 184.3 255.6 24.7 169.1 193.8 
Other immunology— 4.5 4.5 10.5 6.4 16.9 
Total immunology378.5 369.6 748.1 284.8 329.1 613.9 
Neuroscience:
Emgality®
108.3 41.0 149.3 101.5 18.0 119.5 
Zyprexa®
9.6 83.5 93.1 6.9 88.9 95.8 
Cymbalta®
9.1 71.9 81.1 11.0 165.7 176.6 
Other neuroscience26.4 48.0 74.2 22.3 51.1 73.5 
Total neuroscience153.4 244.4 397.7 141.7 323.7 465.4 
Other:
COVID-19 antibodies(4)
1,455.2 14.7 1,469.8 650.6 159.5 810.1 
Cialis®
6.9 210.8 217.7 8.6 118.1 126.8 
Forteo®
70.2 67.3 137.4 97.7 100.8 198.5 
Other50.1 47.8 98.1 54.2 53.4 107.5 
Total other1,582.4 340.6 1,923.0 811.1 431.8 1,242.9 
Revenue$5,174.6 $2,635.4 $7,810.0 $3,941.3 $2,864.3 $6,805.6 
Numbers may not add due to rounding.
(1) Humalog revenue includes insulin lispro.
(2) Jardiance revenue includes Glyxambi®, Synjardy®, and Trijardy® XR.
(3) Olumiant revenue includes sales for baricitinib, for treatment in hospitalized COVID-19 patients, that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.
(4) COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations.
The following table summarizes revenue by geographical area:
Three Months Ended March 31,
20222021
Revenue—to unaffiliated customers(1):
U.S.$5,174.6 $3,941.3 
Europe1,067.3 1,321.2 
Japan410.2 571.8 
China406.5 362.2 
Other foreign countries751.5 609.1 
Revenue$7,810.0 $6,805.6 
Numbers may not add due to rounding.
(1) Revenue is attributed to the countries based on the location of the customer.